Background-Current guidelines recommend intervention for symptomatic aortic stenosis, but the management of asymptomatic aortic stenosis remains controversial. As left ventricular global longitudinal strain (GLS) has been shown to predict cardiovascular outcome, we sought to find whether its use could guide the assessment of risk in these patients. Methods and Results-We prospectively followed 79 patients with severe asymptomatic aortic stenosis (39 men; mean age, 77 ± 12 years; aortic valve [AV] area index, 0.36 cm 2 /m 2 ). In addition to standard echocardiography, speckle strain was measured to assess GLS. Patients were followed for cardiac death and AV replacement driven by symptom development. A multivariable Cox regression was performed to identify associations with events. During 23 ± 20 months, 3 patients had cardiac death and 49 underwent AV replacement. Event-free survival was 72 ± 5% at 1 year, 50 ± 5% at 2 years, and 24 ± 5% at 4 years. Death and AV replacement were predicted by GLS (hazard ratio [HR], 1.14 [95% CI, 1.01-1.28]; P=0.037), as well as extent of AV calcification (HR, 2.44 [95% CI, 1.17-5.12]; P=0.018), peak transaortic pressure gradient (HR, 1.03 [95% CI, 1.01-1.04]; P<0.001), valvulo-arterial impedance (HR, 1.32 [95% CI, 1.04-1.67]; P=0.045), and Society of Thoracic Surgeons Predicted Risk of Morbidity and Mortality (HR, 0.95 [95% CI, 0.90-1.00]; P=0.052).
C alcific aortic stenosis (AS) is the most common cause of aortic valve (AV) disease in developed countries. 1 AS affects 2% to 3% of the North American population aged >65 years 2 and >4% aged >75 years. 3 Between one third and two thirds of patients with severe AS are asymptomatic, [4] [5] [6] and the management of these asymptomatic patients remains controversial. Delaying the surgery may put the patient at risk of sudden death and may lead to irreversible myocardial dysfunction. 7 However, unselected or premature surgery is associated with risks of cardiac surgery and prosthetic complications. 8 Given the chances of adverse outcomes before the development of overt symptoms, investigators have sought to find a reliable approach in which to risk-stratify patients with asymptomatic AS into those who will benefit from surgery before symptom development. 9 
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Clinical outcomes in severe AS have been predicted by valve-specific factors including AV area, AV calcification, transvalvular gradients, and peak aortic velocity, 5, [10] [11] [12] but ventricular factors may also be important. Concentric left ventricular (LV) hypertrophy (LVH), which occurs to compensate for increased wall stress, is a compensatory mechanism which may have detrimental effects, including increased sensitivity to ischemia with consequent systolic or diastolic dysfunction. 13 Earlier AV replacement (AVR) may be considered in asymptomatic AS before severe LVH or dysfunction develops. 14 Subtle LV dysfunction with gradual alteration in both LV systolic and diastolic function might provide another explanation for the benefit of early elective AVR in some asymptomatic patients with AS. 15, 16 To investigate the importance of the valvulo-ventricular interplay in this setting, we studied the incremental prognostic value of LV systolic longitudinal deformation in severe asymptomatic AS. We hypothesized that an indicator of subclinical LV systolic dysfunction, obtained from LV global longitudinal strain (GLS), would provide prognostic information for stratifying the risk of having cardiovascular events in these patients.
Methods

Patient Selection
The study population included patients with severe AS who were studied in our echocardiography laboratory from March 2004 to August 2010. Severe AS was defined as AV area <1 cm 2 or transaortic jet velocity >4 m/s. Patients were excluded if they had any additional hemodynamically significant valvular lesions, presented with symptoms (angina, dyspnea, or syncope) or LV ejection fraction (LVEF)<50%. After these exclusions, we enrolled 79 patients (39 men; 77 ± 12 years; AV area index, 0.36 cm 2 ). The protocol was approved by the institutional review board of the Cleveland Clinic.
Clinical Characteristics
Clinical data were entered prospectively into an electronic health record, including age, sex, height, weight, history of coronary artery disease (previous positive coronary angiogram or stress test), history of diabetes mellitus (fasting blood glucose >126 mg/dL on 2 occasions or patients currently receiving treatment for diabetes mellitus), history of hypercholesterolemia (total cholesterol >190 mg/dL or patients receiving lipid lowering agents), history of hypertension (blood pressure ≥140/90 mm Hg or patients receiving antihypertensive drugs) were collected at baseline. The Society of Thoracic Surgeons (STS) Predicted Risk of Morbidity or Mortality (STS-PRMM) for AV procedures was calculated by entering patient data into an online STS risk calculator (http://riskcalc.sts.org/ STSWebRiskCalc273/). The STS-PRMM uses 24 variables of >50 total risk factors collected by algorithm to predict mortality for valve procedures. 17
Echocardiography
Patients underwent a standard echocardiogram performed by experienced echocardiographers, using commercially available ultrasound systems. The LV dimensions, wall thickness, and outflow tract diameter were measured according to the recommendations of the American Society of Echocardiography. 18 The degree of calcification of the AV was scored as: (1) no calcification; (2) mildly calcified (small isolated foci); (3) moderately calcified (multiple larger foci); and (4) heavily calcified (extensive thickening and calcification of all cusps). AV area was calculated by continuity equation. 19 Stroke volume was calculated by 0.785×(LV outflow tract diameter) 2 ×LV outflow tract velocity-time integral. LVEF was measured by the biplane Simpson method. 20 LV mass was calculated by the American Society of Echocardiography recommended formula. 18 The valvulo-arterial impedance (Zva) was calculated as the sum of the systolic arterial pressure and the mean transvalvular pressure gradient divided by the stroke volume index. 21
Myocardial Deformation
The analysis of LV myocardial deformation was performed with velocity vector imaging (Syngo Velocity Vector Imaging, Siemens Medical Solutions, Ultrasound Division, Mountain View, CA) using speckle-tracking echocardiography for the evaluation of GLS. GLS was derived from the average of the segments strain from the apical long-axis, 4-and 2-chamber views, at a frame rate of >50 frames per second.
Follow-Up
Follow-up information (date of aortic valve replacement or mortality) was obtained from interviews with the patients, their relatives, or their physicians. The composite end point was cardiac death and AVR necessitated by symptom development. Information regarding cause of death was obtained from review of death certificates. Only cardiac death directly related to AS (death from congestive heart failure or sudden death) was included as an outcome.
Statistical Analysis
Continuous data are expressed as mean±SD. Statistical analysis was performed with standard software (SPSS, version 16, Chicago, IL). Group comparisons were obtained with χ 2 for categorical data or 1-way ANOVA for continuous variables. Statistical significance was defined by P<0.05. Kaplan-Meier curves were used for cumulative survival analysis, and multivariable Cox regression was used to identify associations of events. The differences between models were tested by calculating the overall difference in −2 log likelihood χ 2 between models. 
Reproducibility of Measurements
For the GLS measurement, 11 patients (33 images) were randomly selected and measured for the interobserver and intraobserver variability. The interclass coefficient for intraobserver variability was 0.72 (P=0.004). The coefficient of variation for interobserver variability was 0.09 (range, 0.03-0.26).
Results
Patient Characteristics
Clinical characteristics of the patients are listed in Table 1 . Most patients (n=68, 86%) had calcific AS, with a range of indexed AV area from 0.17 to 0.56 cm 2 /m 2 and aortic jet velocity from 4.0 to 5.9 m/s. Mean LVEF was 64 ± 8%. A history of coronary artery disease was noted in 27 patients (33%), and most patients had cardiovascular risk factors.
Outcomes
Follow-up information was available for all patients. During the median follow-up period of 16 months, there were 5 deaths and 49 valve replacements because of the development of symptoms. Three of 5 deaths were because of cardiac causes (2 because of congestive heart failure and 1 sudden death). Two of these patients refused surgery and AVR was not performed on the third because of advanced colonic carcinoma. Of the 2 noncardiac deaths, one was because of malignancy and the other Alzheimer disease. The event-free survival was 72 ± 5% at 1 year, 50 ± 5% at 2 years, and 24 ± 5% at 4 years ( Figure 1 ).
Associations of Outcomes
Female sex, AV area index, peak aortic velocity, mean pressure gradient, AV calcification score 3 or 4, Zva, and GLS were univariable predictors of subsequent outcome ( Table 2 ). To select one of the 3 correlates of AS severity for multivariate analysis, we performed a series of nested models by adding each one of the AS severity into the clinical variables (STS-PRMM). Transaortic peak pressure gradient had a better performance compared with the mean pressure gradient and AV area ( Figure 2 ). Multivariable Cox regression analysis (Table 3) showed that GLS was associated with events, as well as STS-PRMM, AV calcification score, AV area, and Zva.
Nested Cox models showed that GLS was also incremental to other variables (Figure 3 ). In these nested models, the predictive power of clinical risk factors (STS-PRMM) was significantly strengthened by addition of severe AV calcification, transaortic peak pressure gradient, aortic impedance. However, the prognostic power of this model was further improved by the addition of GLS.
To find the appropriate cut-off value to GLS as a predictor of the outcome, we created several models using different cutoff values of GLS. Using the −2 log likelihood χ 2 to select the model with the best performance, the model using mean absolute GLS >15% had the best performance in predicting the outcome (Figure 4 ).
Discussion
The decision whether or not to perform AVR in patients with asymptomatic severe AS is a clinical dilemma. The results of this study were that, as well as transaortic peak pressure gradient, severe AV calcification and Zva, GLS was associated with subsequent cardiovascular outcome in asymptomatic severe AS. These findings show the role of long-axis LV function as a predictor of outcome in an asymptomatic group, incremental to other known predictors of outcome.
Predictors of Outcome in Asymptomatic AS
In this study, AVR was used as a surrogate for symptom onset, the timing of which is hard to pinpoint from the history. This use of AVR as an end point is consistent with the asymptomatic AS literature, 22 and on the basis of the concept that AVR in the asymptomatic phase is justifiable if AVR is likely to be required soon, especially if the patient lives remotely or delays are likely once they become symptomatic.
Most of the established correlates of outcome in AS are valvular. Previous work has shown AV area to predict the development of cardiac symptoms and AV velocity to be associated with all-cause mortality. 5 Although STS score has been designed to evaluate operative mortality, recent work has shown that for patients with asymptomatic severe AS, STS score is a powerful tool for predicting long-term outcome. 22 Moreover, Zva is a marker of global LV afterload in patients with AS, and the only hemodynamic factor also associated with LV diastolic and systolic dysfunction. 21 In 128 patients with severe AS, Rosenhek et al 10 showed AV calcification by echocardiography to be significantly correlated with death or the development of symptoms leading to AVR. Similarly, the evaluation of AV calcium score by multi-slice computed tomography was shown by Feuchtner et al 23 to predict shortterm outcomes in patients with asymptomatic severe AS. Our study confirmed that AS severity, as measured by aortic valve area, transaortic peak and mean pressure gradient, as well as severe AV calcification were predictors of clinical outcome.
Currently, ejection fraction is the LV function parameter that is most used in decision-making to operate on asymptomatic AS. 24 However, LVEF is not a good surrogate marker of midwall shortening, 25 and a preserved LVEF can be misleading as a marker of LV systolic function in patients with AS because patients with normal LVEF can have a low cardiac index 26 in the setting of LVH. 27 Increased LV mass is associated with an increased rate of cardiovascular events in AS, 28 and severe LVH is associated with decreased long-term survival after AVR. 14 Patients with AS may have interstitial myocardial fibrosis which starts in the subendocardial layer and may involve the whole myocardium. These processes contribute to diastolic dysfunction, remodeling, and eventually systolic heart failure. It has been speculated, however, that myocardial fibrosis and severe LVH that may not be reversible after delayed surgery could preclude an optimal postoperative long-term outcome. 29 Previous studies have shown longitudinal function to be an important marker of myocardial function in patients with severe AS and normal LVEF. [30] [31] [32] LV longitudinal shortening is more closely associated than ejection fraction with changes in symptom status, and may closely reflect alterations in subendocardial myocardial function. 31 Despite the absence of symptoms and a normal LVEF, patients with severe AS have an increased Zva. 33 In addition, this increased global afterload seems closely related to preclinical myocardial changes, identifiable by 2-dimensional strain, independent of the AS severity. This indicates that LV mechanics is affected both by the arterial and the valvular load.
Recent work by Monin et al 34 and Lancellotti et al 35 has documented the importance of the valvular, arterial, and ventricular interplay in patients with asymptomatic moderate to severe AS, and developed a risk score for predicting the outcomes in these patients. Although the main results were consistent with the ability of GLS, Zva, and other variables that predicted outcomes, our study shows GLS to provide incremental prognostic information to these previously known factors.
Limitations
The primary limitation is that this small, elderly study group may be reflective of our practice. The decision to perform AVR was made by the attending cardiologist, and so AVR could be considered as a soft event. Not all patients went to surgery, and the group that underwent surgery had a lower STS score, indicating some selection bias. However, in the present study, surgery was mainly dictated by the development of symptoms. The use of exercise testing or measurement of type B natriuretic peptide are potential means of assessing functional class or defining hemodynamic effect of AS in asymptomatic patients, and were only performed in a subgroup in this study. However, resting strain measurement, which is a simple adjunct to the resting echocardiogram, may be a less expensive means of understanding risk in AS patients. GLS may be influenced by a variety of pathologies, including myocardial ischemia and infarction, diabetes mellitus and hypertension. Although the role of strain is independent of valvular impedance, hypertension and diabetes mellitus were certainly prevalent in this population. However, this lack of specific cause does not limit the parameter as a functional marker of risk, irrespective of the cause of reduced strain. Finally, serial echocardiographic examinations were available in a limited number of patients, and the potential impact of the rate of progression could not be evaluated. An ongoing study would be needed to further investigate the effect of AVR on GLS.
Conclusion
The results of this study emphasize that both the state of the valve and the LV must be considered when assessing risk in asymptomatic patients. GLS is not only an independent predictor of outcomes in patients with severe asymptomatic AS but also incremental to other clinical and echocardiographic variables.
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